LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・Exelixis Inc

Exelixis Inc

Затворен

СекторЗдравеопазване

52.52 1.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

51.42

Максимум

52.78

Ключови измерители
By Trading Economics
Приходи	-34M 210M
Продажби	12M 611M
P/E Средно за сектора	16.649 49.888
EPS	0.87
Марж на печалбата	34.457
Служители	1,077
EBITDA	15M 258M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	-1.73% downside

Дивиденти
By Dow Jones
Следващи печалби	27.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.4B 13B
Предишно отваряне	50.66
Предишно затваряне	52.52

Настроения в новините

By Acuity

50%

154 / 344 Класиране в Healthcare

Exelixis Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.06.2026 г., 23:22 ч. UTC

Печалби

Значими двигатели на пазара

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3.06.2026 г., 23:09 ч. UTC

Горещи акции

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3.06.2026 г., 20:51 ч. UTC

Печалби

Costco Reports 15% Sales Growth in May

3.06.2026 г., 20:43 ч. UTC

Печалби

Broadcom 2Q Revenue Climbs on AI Chip Demand

3.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.06.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Futures Fall on Possible Technical Correction -- Market Talk

3.06.2026 г., 23:15 ч. UTC

Пазарно говорене

Печалби

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3.06.2026 г., 22:08 ч. UTC

Горещи акции

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3.06.2026 г., 21:54 ч. UTC

Пазарно говорене

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3.06.2026 г., 21:18 ч. UTC

Печалби

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3.06.2026 г., 21:15 ч. UTC

Печалби

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3.06.2026 г., 21:13 ч. UTC

Печалби

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3.06.2026 г., 21:13 ч. UTC

Печалби

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3.06.2026 г., 21:12 ч. UTC

Печалби

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3.06.2026 г., 21:09 ч. UTC

Печалби

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3.06.2026 г., 21:03 ч. UTC

Печалби

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.06.2026 г., 20:43 ч. UTC

Печалби

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3.06.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3.06.2026 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3.06.2026 г., 20:35 ч. UTC

Печалби

Broadcom Stock Falls Despite Record Results -- Barrons.com

3.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3.06.2026 г., 20:17 ч. UTC

Печалби

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3.06.2026 г., 20:17 ч. UTC

Печалби

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q Adj EPS $2.44 >AVGO

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q EPS $1.91 >AVGO

3.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q Rev $22.19B >AVGO

Сравнение с други в отрасъла

Ценова промяна

Exelixis Inc Прогноза

Ценова цел

By TipRanks

-1.73% надолу

12-месечна прогноза

Среден 47.7 USD -1.73%

Висок 56 USD

Нисък 40 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Exelixis Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Exelixis Inc през последните 3 месеца.

Настроение

By Acuity

154 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.